Immunicum AB Publishes Prospectus in Connection with Rights Issue and Listing on Nasdaq Stockholm 5 December 2017 Read more R
Immunicum Announces Report from the Extraordinary General Meeting on December 4, 2017 4 December 2017 Read more R
Immunicum Announces Positive Preliminary Results from Proof-of-Concept Animal Study Testing Combination of Ilixadencel and Checkpoint Inhibitors 27 November 2017 Read more R
Nasdaq Stockholm's Listing Committee Has Approved Immunicum's Shares for Listing on Nasdaq Stockholm Conditional Upon Completion of the Rights Issue 24 November 2017 Read more R
Immunicum AB (publ) and Academic Collaborators Publish Preclinical Ilixadencel Mode of Action Data in Journal Oncoimmunology 10 November 2017 Read more
Immunicum AB (publ) Presents Further Preclinical Ilixadencel Mode of Action Data at Annual SITC Meeting 7 November 2017 Read more
The Board of Directors of Immunicum AB (publ) Resolves on a 90% Secured Rights Issue of up to SEK 223 Million to Finance Further Development of its Portfolio 2 November 2017 Read more R
Immunicum AB (publ) Announces Appointment of Sharon Longhurst as Head of CMC 10 October 2017 Read more
Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study 28 September 2017 Read more R
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US 21 September 2017 Read more
Immunicum AB (publ) Announces Upcoming Presentations at Conferences in August and September 22 August 2017 Read more
Immunicum AB (publ) Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel 17 August 2017 Read more R
Immunicum AB (publ) Announces Last Patient Last Visit in the Ongoing Phase I/II Hepatocellular Carcinoma Study 15 August 2017 Read more
Immunicum AB (publ) Announces Enrollment of First United States Patient in the Ongoing Phase 2 MERECA Trial for Ilixadencel 10 August 2017 Read more
Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma 20 June 2017 Read more R
Immunicum AB (publ) Announces Approval of the International Nonproprietary Name (INN) ilixadencel for INTUVAX® 12 June 2017 Read more
Report from the Annual General Meeting of Immunicum AB (publ) on April 26, 2017 26 April 2017 Read more R
Immunicum AB Announces Enrollment of First Patient in Phase I/II GIST Trial Following Study Protocol Amendment 7 March 2017 Read more R
Immunicum AB Appoints Sijme Zeilemaker as Senior Director Business Development 2 March 2017 Read more R
Immunicum AB Announces Presentations and Participations at Upcoming Conferences in March 1 March 2017 Read more
Immunicum AB announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma 14 February 2017 Read more R
Immunicum Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Webcast 9 February 2017 Read more R
Immunicum AB Publishes Prospectus in Connection with Rights Issue and Listing on Nasdaq Stockholm 5 December 2017 Read more R
Immunicum Announces Report from the Extraordinary General Meeting on December 4, 2017 4 December 2017 Read more R
Immunicum Announces Positive Preliminary Results from Proof-of-Concept Animal Study Testing Combination of Ilixadencel and Checkpoint Inhibitors 27 November 2017 Read more R
Nasdaq Stockholm's Listing Committee Has Approved Immunicum's Shares for Listing on Nasdaq Stockholm Conditional Upon Completion of the Rights Issue 24 November 2017 Read more R
The Board of Directors of Immunicum AB (publ) Resolves on a 90% Secured Rights Issue of up to SEK 223 Million to Finance Further Development of its Portfolio 2 November 2017 Read more R
Immunicum AB (publ) Announces Completion of HCC Phase I/II Clinical Study 28 September 2017 Read more R
Immunicum AB (publ) Completes Strategic Analysis and Defines Updated Clinical Development Plan for Ilixadencel 17 August 2017 Read more R
Immunicum Announces Publication in Journal for ImmunoTherapy of Cancer of Results Overview from Ilixadencel's First Clinical Study in Metastatic Renal Cell Carcinoma 20 June 2017 Read more R
Report from the Annual General Meeting of Immunicum AB (publ) on April 26, 2017 26 April 2017 Read more R
Immunicum AB Announces Enrollment of First Patient in Phase I/II GIST Trial Following Study Protocol Amendment 7 March 2017 Read more R
Immunicum AB Appoints Sijme Zeilemaker as Senior Director Business Development 2 March 2017 Read more R
Immunicum AB announces approval in France for its Clinical Trial Application for INTUVAX in metastatic renal cell carcinoma 14 February 2017 Read more R
Immunicum Announces Fourth Quarter and Year End 2016 Financial Results and Corporate Update Webcast 9 February 2017 Read more R
